INTRODUCTION {#s1}
============

Although young women only account for 7% of all breast cancers, it is the most common cancer among young females \[[@R1]\]. Yet, young age at diagnosis of breast cancer has emerged as an independent factor for higher recurrence risk and death in various studies \[[@R2]--[@R6]\]. Breast cancer in young women has been described to have more biologically aggressive tumours (basal and HER2-enriched subtypes) than in older counterparts, which has been associated with a poorer prognosis \[[@R6]\]. Several factors influence poor prognosis in the young subgroup, such as higher tumour grade at diagnosis, high tumour proliferation, increased expression of HER-2 (*ERB-B2*) and reduced expression of both estrogen (ER) and progesterone receptor (PR) \[[@R7]\]. These women often struggle with life issues that are either absent or much less severe in older women, such as the possibility of early menopause and effects on fertility. While clinicopathologic differences point to underlying biological differences between breast tumours found in younger versus older women, limited studies have documented age-related changes at the molecular level.

Cancer progression is impelled by the accumulation of somatic genetic mutations, which consists of single nucleotide substitutions, translocations and somatic mutations \[[@R8]\]. Somatic mutations are non-heritable alterations to the human genome that occur spontaneously in somatic cells, which is often due to DNA replication error or chemical/ultraviolet (UV) radiation. Copy number alterations (CNA) are somatic changes in the copy numbers of a DNA sequence that arise during the process of cancer development. They consist of changed chromosome structure in the form of gain or loss in copies of DNA segments, and are prevalent in many types of cancer \[[@R9]\]. Investigating these genomic alterations in breast cancer patients can not only offer valuable insights into breast cancer pathogenesis and discover potential biomarkers, but also provide novel drug targets for better therapeutic treatment options \[[@R10]\]. Several cytogenetic and array-based studies have detected recurrent alterations linked with certain cancer types, and have found CNAs to be a particularly common genetic mutation in cancer \[[@R11], [@R12]\]. In addition, some of these CNAs have resulted in the discovery of disease causal genes and novel therapeutic targets, and have been strongly associated with clinical phenotypes \[[@R13]--[@R16]\]. For example, the use of vemurafenib to inhibit BRAF V600E mutation has shown remarkably improved survival in melanoma patients \[[@R17]\]. In another study, treatment with tyrosine kinase inhibitors for EGFR in lung cancer has also shown great success \[[@R18]\].

Since CNAs often encompass genes, it is suspected that they may greatly influence gene expression within the CNA regions. Indeed, several studies have reported a correlation between CNA and the average global expression levels of genes located within the copy number variable chromosomal regions. For instance, one group has shown that in tumour formation from an immortalized prostate epithelial cell line, 51% of genes with increased expression were mapped to DNA gain regions and 42% of genes with decreased expression were mapped to DNA loss regions \[[@R19]\]. This was further supported by another group working with breast tumour cell lines, noting that DNA copy number influences gene expression across a range of CNAs, with 62% of amplified genes resulting in moderately or highly elevated expression of the genes within the amplified regions \[[@R20]\].

Therefore, investigation of CNAs offers the potential to gain insight into the underlying genetic composition of breast tumours in young women. Mining genome-wide profiles will help find breast cancer genes and pathways with strong potential for prognostic significance as a function of age. Given that approximately 40--50% of young breast cancer patients relapse after 5 years \[[@R21]\], these age-specific signatures could also serve as a treatment decision tool to identify young patients that would gain more benefit from particular adjuvant therapies.

RESULTS {#s2}
=======

Clinical characteristics {#s2_1}
------------------------

The young patients with breast cancer in the Discovery and Validation Data sets retrieved from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) \[[@R22]\] have very similar distribution in age, menopausal status, tumour grade, tumour size, ER, PR expression and HER2 expressions (*p* \> 0.05) (Table [1](#T1){ref-type="table"}). On the other hand, the two sets have statistically significant differences in the tumour stage, with young patients in the Discovery set having a much higher prevalence in stage 0 compared to the Validation set (43.1% vs 0.8%) and PAM50 subtypes (*p* \< 0.05). However, an overall pattern of the basal subtype being the most frequent amongst young patients is apparent in both the Discovery and Validation dataset. It must be indicated that there are 50 patients in Validation set without stage information, which may affect the analysis of difference in distribution of stages between the two sets. Since our focus is only on those Discovery set CNA candidates that are validated in the Validation set, the stage difference is unlikely to be driving CNA selection. Furthermore, it is our intention to investigate whether tumours in young women share commonalities in genetic alterations, regardless of stages and subtypes.

###### Clinical characteristics table comparing the METABRIC discovery dataset and validation dataset for young patients only

  Characteristic             Discovery Young     Validation Young   ^†^*P*-value
  -------------------------- ------------------- ------------------ --------------
  **Age^\*^**                40 (36, 43)         40 (37, 43)        1
  **Menopausal Status**                                             0.5
  *Pre*                      127 (97.7%^\*\*^)   125 (100%)         
  *Post*                     2 (1.5%)            0 (0.0%)           
  **Subtype**                                                       \<0.001
  *Normal*                   11 (8.5%)           25 (20%)           
  *LumA*                     41 (31.5%)          18 (14.4%)         
  *LumB*                     20 (15.4%)          9 (7.2%)           
  *Her2*                     16 (12.3%)          21 (16.8%)         
  *Basal*                    42 (32.3%)          52 (41.6%)         
  **Grade**                                                         0.98
  *1*                        7 (5.4%)            6 (4.8%)           
  *2*                        37 (28.5%)          34 (27.2%)         
  *3*                        86 (66.1%)          81 (64.8%)         
  **Stage**                                                         \<0.001
  *0*                        56 (43.1%)          1 (0.8%)           
  *1*                        25 (19.2%)          28 (22.4 %)        
  *2*                        42 (32.3%)          35 (28.0%)         
  *3*                        7 (5.4%)            11 (8.8%)          
  *4*                        0 (0.0%)            0 (0.0%)           
  **ER-expr**                                                       0.09
  *+*                        74 (56.9%)          57 (45.6%)         
  *--*                       56 (43.1%)          68 (54.4%)         
  **PR-expr**                                                       0.78
  *+*                        55 (42.3%)          56 (44.8%)         
  *--*                       75 (57.7%)          69 (55.2%)         
  **Her2-expr**                                                     0.27
  *+*                        22 (16.9%)          29 (23.2%)         
  *--*                       108 (83.1%)         96 (76.8%)         
  **Tumour Size^\*^ (mm)**   22 (16,30)          (17,30)            1

^\*^For continuous variables (Age, Tumour size), quantiles (50th percentile (25th percentile, 75th percentile)) were presented.

^†^*P*-values were determined by Wilcoxon rank sum test for continuous variables and Fisher's exact test for categorical variables.

^\*\*^The proportion was obtained by dividing the total number of patients.

Identification of recurrent CNA regions {#s2_2}
---------------------------------------

Figure [1](#F1){ref-type="fig"} shows the analysis flowchart to identify age-related recurrent CNA regions using our maximal clique-based recurrent CNA detection algorithm. In the METABRIC Discovery cohort 867 of the total 997 patients are classified into the old age group (≥45 years old) and 130 patients into the young age group. In the Validation cohort 870 of the total 995 patients are classified into the old age group and 125 patients into the young age group. After applying filtering criteria (retaining CNA data that was generated by ≥10 probes and having a CNA size of at least 1 kb), for the old age cohort in the Discovery set, there are 96,503 and 47,943 individual patient level CNA gain and loss regions respectively. For the young age cohort, there are 14,957 and 6,373 individual patient level CNA gain and loss regions, respectively.

![Analysis flowchart for identifying recurrent CNA regions\
Recurrent CNA regions are identified from young and old patient cohorts in the Discovery set of METABRIC. The identified recurrent CNA regions are then validated in the Validation set of METABRIC.](oncotarget-09-11541-g001){#F1}

Upon filtering for recurrent CNA regions of at least 1 kilobase (kb) in size and having at least 5 patients per recurrent region identified from the recurrent CNA calling algorithm, there are a total of 1,086 recurrent CNA gain regions (554 of the 1,086 gain regions encompassing protein encoding genes) and 439 recurrent CNA loss regions (202 of the 439 loss regions encompassing protein encoding genes). These regions are uniquely found in the young age group and form the young-specific recurrent gain and loss regions in the Discovery set.

Validation testing is then performed using the Validation set, which contains 995 patients. All filtering criteria and algorithm implementations follow the same procedure as the Discovery dataset analysis. For recurrent CNA gain regions, a total of 81 of the 1,086 regions have been validated (found in both the Discovery and Validation datasets), in which 30 regions have encompassed 29 unique protein encoding genes (Table [2](#T2){ref-type="table"}). For recurrent CNA loss regions, a total of 25 of the 439 regions have been validated, in which 8 regions encompassed 10 unique protein encoding genes (Table [3](#T3){ref-type="table"}). In total, 38 validated recurrent CNA regions with 39 protein encoding genes were identified, along with 51 validated recurrent gain CNA regions ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}) and 17 validated recurrent loss CNA regions ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}) that did not encompass any protein encoding genes.

###### Validated recurrent gain CNA regions with genes

  Chr   Inner Start   Inner End   Inner Size   Outer Start   Outer End   Outer Size   Gene Symbol         Size1   Size2
  ----- ------------- ----------- ------------ ------------- ----------- ------------ ------------------- ------- -------
  1     84551640      84565561    13921        84481190      84729446    248256       SAMD13              5       6
  1     143607802     143609034   1232         143607067     143609055   1988         PDE4DIP             20      30
  1     191374290     191385577   11287        191359529     191405183   45654        CDC73               40      50
  1     191385797     191402004   16207        191359529     191405183   45654        CDC73               40      50
  1     222004315     222004925   610          221990859     222005526   14667        CAPN2               48      47
  3     176423680     176427601   3921         176415397     176428705   13308        NAALADL2            18      22
  3     176428607     176428705   98           176415397     176470832   55435        NAALADL2            18      22
  5     22246497      22346803    100306       22194503      22414425    219922       CDH12               12      11
  6     34625387      34634997    9610         34624907      34656516    31609        SPDEF               9       9
  7     134782461     134787038   4577         134782461     134792291   9830         CNOT4               11      13
  7     142150844     142154230   3386         142150819     142154515   3696         PRSS1               7       10
  8     40695071      40697114    2043         40693570      40699795    6225         ZMAT4               17      16
  9     93166194      93261927    95733        93157333      93373420    216087       NFIL3               5       7
  10    5737990       5742226     4236         5736767       5744158     7391         ASB13               24      32
  10    14598341      14600566    2225         14477106      14629604    152498       FAM107B             19      27
  11    4931741       4932834     1093         4931741       4932966     1225         MMP26; OR51A2       7       11
  12    180797        191614      10817        180797        195197      14400        SLC6A12             14      24
  12    7895693       7897774     2081         7895693       7897774     2081         SLC2A14             13      23
  12    7899067       7905082     6015         7899067       7909593     10526        SLC2A14             13      23
  13    112354883     112363586   8703         112333434     112363586   30152        C13orf35            10      7
  13    113356126     113365589   9463         113345036     113371998   26962        ATP4B               10      9
  17    43751830      43753351    1521         43722185      43756717    34532        SKAP1               9       14
  17    45136676      45139395    2719         45134175      45142242    8067         SLC35B1             21      18
  18    9549925       9575313     25388        9417006       9594232     177226       PPP4R1              5       7
  18    43704001      43707399    3398         43703934      43707399    3465         SMAD2               6       6
  19    40629439      40647918    18479        40620640      40702499    81859        FFAR2               13      13
  19    60890917      60901410    10493        60890917      60904859    13942        EPN1                8       11
  20    14741416      14743670    2254         14741416      14743754    2338         MACROD2             8       10
  20    41215727      41219453    3726         41202818      41220578    17760        PTPRT               12      18
  22    20146692      20170596    23904        20145867      20170766    24899        PI4KAP2; TMEM191C   7       15

The first seven columns represent the chromosome number, inner and outer start and end coordinates of the recurrent CNA region, and the size of the region in base pairs (hg18). The last three columns are the genes encompassed in each CNA region, followed by the sample size (no. of cases) in both Discovery and Validation dataset (Chr: Chromosome; Size 1: Discovery Cluster Size; Size 2: Validation Cluster Size).

###### Validated recurrent loss CNA regions with genes

  Chr   Inner Start   Inner End   Inner Size   Outer Start   Outer End   Outer Size   Gene Symbol      Size1   Size2
  ----- ------------- ----------- ------------ ------------- ----------- ------------ ---------------- ------- -------
   2    97507180      97517476    10296        97507180      97520698    13518        ANKRD36B         5       5
   3    62243538      62257523    13985        62242606      62277516    34910        PTPRG            6       6
   4    59521         61566       2045         59521         64435       4914         ZNF718; ZNF595   13      6
   7    38296343      38297866    1523         38295506      38297939    2433         TRGV11           18      22
   8    14388851      14391732    2881         14385622      14391732    6110         SGCZ             23      18
   9    5027454       5029342     1888         5027454       5030334     2880         JAK2             7       11
  10    89710114      89713882    3768         89708179      89713882    5703         PTENP1; PTEN     10      10
  17    21245986      21253816    7830         21227031      21271210    44179        KCNJ12           15      9

The first seven columns represent the chromosome number, inner and outer start and end coordinates of the recurrent CNA region, and the size of the region in base pairs (hg18). The last three columns are the genes encompassed in each CNA region, followed by the sample size in both Discovery and Validation dataset (Chr: Chromosome; Size 1: Discovery Cluster Size; Size 2: Validation Cluster Size).

Figure [2](#F2){ref-type="fig"} shows an overview of how similar the cluster sizes (i.e. number of patients) are in the Discovery set versus the Validation set for all the identified young-specific recurrent CNA regions. It can be seen that for both gain and loss regions, cluster sizes in the Discovery and Validation datasets have a fairly linear relationship. For example, if 30% of the young patients in the Discovery set harbour a CNA region, it is likely that around 30% of patients in the Validation set will harbour that region as well.

![Scatter plot showing the cluster sizes of recurrent CNA regions in the discovery and validation sets\
(**A**) Gain recurrent young-specific regions and (**B**) Loss recurrent young-specific regions. Each point on the plot represents a young-specific recurrent CNA region. Blue represents regions without genes, and orange represents regions with genes.](oncotarget-09-11541-g002){#F2}

Annotation of the identified recurrent CNA regions {#s2_3}
--------------------------------------------------

We performed region-based variation annotation on the identified young-specific recurrent CNA regions (see Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} and [Supplementary Tables 1](#SD2){ref-type="supplementary-material"} and [2](#SD1){ref-type="supplementary-material"}) with refGene using the software ANNOVAR (Annotate Variation). The complete annotation information of the recurrent CNA regions is shown in [Supplementary Table 3](#SD3){ref-type="supplementary-material"}. Figure [3](#F3){ref-type="fig"} shows the genome location distribution of our recurrent CNAs with respect to the encompassed regions. The majority of the CNAs are in non-coding regions (76%) and 24% in coding regions.

![Distribution of the identified young-specific recurrent CNA regions with respect to the genome location\
The functional annotation of the young-specific recurrent CNA regions is based on software ANNOVAR.](oncotarget-09-11541-g003){#F3}

In order to better visualize the mutation distribution of the 39 genes encompassed in the recurrent CNAs identified in the coding regions in both the Discovery and Validation young women group, an R package called the ComplexHeatmap was applied (Figure [4](#F4){ref-type="fig"}). From the heatmap, it can be observed that CNA gain regions encompassing genes *CAPN2, CDC73* and *ASB13* are the top 3 most frequent in both Discovery and Validation dataset (young women age group), while gene *SGCZ* ranks top for recurrent CNA loss regions in the two datasets.

![Heatmap of mutation distribution for genes identified in the recurrent young-specific CNA gain and loss regions\
(**A**) Results from the Discovery dataset and (**B**) Results from the Validation dataset. Rows are sorted based on the frequency of the alterations in all young-specific samples and columns are sorted to visualize the mutual exclusivity across genes. Barplots at both sides of the heatmap show numbers of different alterations for each sample and for each gene. Red represents CNA loss mutations and blue represents CNA gain mutations.](oncotarget-09-11541-g004){#F4}

Expression quantitative trait locus analysis {#s2_4}
--------------------------------------------

An overview of the expression levels for each of the identified young-specific genes across all the young patients samples in the Discovery (Figure [5A](#F5){ref-type="fig"}) and Validation datasets (Figure [5B](#F5){ref-type="fig"}) is provided as gene expression heatmaps. Further interrogation using logistic regression was performed to evaluate the statistical association between gene expression and CNA mutation status (Table [4](#T4){ref-type="table"}). In total, 16 gain regions and 1 loss region show significant associations with their gene expression changes. However, the directionality of the association is ambiguous. Fourteen out of the 16 gain regions correlated with high gene expression while the other 2 gain regions (encompassing *MMP26* and *SPDEF*) were associated with low gene expression. For example, mutated gain CNA status in *ASB13* seems to lead to higher gene expression. On the other hand, the loss region encompassing *PTEN* was found to be associated with having high gene expression level.

![Heatmap of gene expression for the genes identified in the recurrent young-specific CNA regions in young breast cancer patients\
(**A**) Results from the Discovery dataset (**B**) Results from the Validation dataset. Rows represent the gene expression levels for the genes identified in the recurrent young-specific CNA gain and loss regions (same order as in Figure [4](#F4){ref-type="fig"} for comparison). Columns represent the young-specific samples in Discovery and Validation datasets. The higher the intensity of the red colour, the higher the gene expression level.](oncotarget-09-11541-g005){#F5}

###### Logistic regression analysis between CNA mutation status and gene expression in combined dataset

  Gene Symbol   Copy Number State   *P*-value   Odds Ratio^†^          Discovery Sample Size   Validation Sample Size
  ------------- ------------------- ----------- ---------------------- ----------------------- ------------------------
  ASB13         Gain                0.049       1.83 (1.00--3.34)      24                      32
  ATP4B         Gain                0.021       3.51 (1.21--10.17)     10                      9
  CAPN2         Gain                0.00002     3.21 (1.89--5.45)      48                      47
  CDH12         Gain                0.026       2.87 (1.14--7.24)      12                      11
  CNOT4         Gain                0.0004      7.45 (2.46--22.49)     11                      13
  EPN1          Gain                0.004       9.57 (2.15--42.56)     8                       11
  PDE4DIP       Gain                0.002       2.73 (1.45--5.15)      20                      30
  PI4KAP2       Gain                0.031       2.81 (1.10--7.14)      7                       15
  PPP4R1        Gain                0.016       6.7 (1.44--31.23)      5                       7
  SLC35B1       Gain                0.001       19.19 (6.54--56.27)    21                      18
  SMAD2         Gain                0.022       6.06 (1.30--28.22)     6                       6
  SPDEF         Gain                0.057       0.39 (0.15--1.03)      9                       9
  FAM107B       Gain                0.083       1.79 (0.93-3.46)       19                      27
  MACROD2       Gain                0.085       2.73 (0.87-8.55 )      8                       10
  MMP26         Gain                0.098       0.43 (0.15-1.17)       7                       11
  NFIL3         Gain                0.068       3.46 (0.91-13.08)      5                       7
  PTEN          Loss                0.002       29.12 (3.83--221.25)   10                      10

^†^Odds ratio is followed by its corresponding 95% confidence interval in brackets.

Survival analysis {#s2_5}
-----------------

We further evaluate whether the expression levels of these genes are associated with disease-specific survival (DSS) (Table [5](#T5){ref-type="table"}). The expression levels of eight out of the 39 young-specific genes are significantly associated with survival outcome. A higher gene expression of genes *CAPN2*, *NFIL3* and *SLC35B1* was associated with a moderately worse survival outcome.

###### Cox proportional hazard analysis of disease (breast cancer) specific survival of gene expression in combined dataset (discovery and validation)

  Genes     CNA types   *P*-value   Hazard ratio^†^     Discovery Sample Size   Validation Sample Size   Chr   InnerStart   InnerEnd
  --------- ----------- ----------- ------------------- ----------------------- ------------------------ ----- ------------ -----------
  ASB13     Gain        0.0001      0.54 (0.39--0.73)   24                      32                       10    5737990      5742226
  CAPN2     Gain        0.091       1.54 (0.93--2.54)   48                      47                       1     222004315    222004925
  NFIL3     Gain        0.009       1.58 (1.13--2.23)   5                       7                        9     93166194     93261927
  PDE4DIP   Gain        0.027       0.37 (0.16--0.89)   20                      30                       1     143607802    143609034
  PTPRT     Gain        0.0002      0.68 (0.55--0.83)   12                      18                       20    41215727     41219453
  SKAP1     Gain        0.0002      0.66 (0.53--0.82)   9                       14                       17    43751830     43753351
  SLC35B1   Gain        0.00005     1.88 (1.39--2.55)   21                      18                       17    45136676     45139395
  JAK2      Loss        0.007       0.43 (0.24--0.79)   7                       11                       9     5027454      5029342

^†^Hazard ratio is followed by its corresponding 95% confidence interval in brackets.

Of particular interest, the mutation status of two genes, *ASB13* (Figure [6A](#F6){ref-type="fig"}) and *SGCZ* (Figure [7D](#F7){ref-type="fig"}), was also significant in the Kaplan Meier survival analysis, which allows estimation of a survival curve over time. Patients with a mutated status in both of these genes resulted in a worse survival outcome when compared to patients without the gene mutations. Other genes found to be significant in the survival analysis include *ATP4B* (Figure [6B](#F6){ref-type="fig"}), *FFAR2* (Figure [6C](#F6){ref-type="fig"}) and *PTPRT* (Figure [6D](#F6){ref-type="fig"}), all encompassed within CNA gain regions. *PTENP1* (Figure [7A](#F7){ref-type="fig"}), *PTEN* (Figure [7B](#F7){ref-type="fig"}), *ZNF718* (Figure [7C](#F7){ref-type="fig"}) and *ZNF595* (Figure [7E](#F7){ref-type="fig"}), all encompassed in CNA loss regions.

![Kaplan-Meier survival analysis for genes with significant CNA gain mutations in the young women group\
Genes showing with statistical significance (*p* \< 0.05) are (**A**) ASB13, (**B**) ATP4B, (**C**) FFAR2 and (**D**) PTPRT. Survival curve in red represents patients without CNA mutation in the corresponding gene (CN = 2) while the curve in blue represents patients with CNA gain mutations in the corresponding gene (CN \> 2). Y-axis is the cumulative survival probability and X-axis is the survival time in years.](oncotarget-09-11541-g006){#F6}

![Kaplan-Meier survival analysis for genes with significant CNA loss mutations in the young women group\
Genes showing statistical significance (*p* \< 0.05) are (**A**) PTENP1, (**B**) PTEN, (**C**) ZNF718, (**D**) SGCZ and (**E**) ZNF595. Survival curve in red represents patients without CNA mutation in the corresponding gene (CN = 2) while the curve in blue represents patients with CNA loss mutations in the corresponding gene (CN \< 2). Y-axis is the cumulative survival probability and X-axis is the survival time in years.](oncotarget-09-11541-g007){#F7}

Cancer-relevant candidate genes {#s2_6}
-------------------------------

PTEN (Phosphatase and tensin homolog) {#s2_7}
-------------------------------------

Results from our study show that the median survival time (i.e. half of the patients are expected to be alive) for young patients with a copy number loss in the *PTEN* gene region is \~4 years as opposed to \~15 years for those without. *PTEN* (cytoband 10q23.31) has been identified as a tumour suppressor which inhibits the PI3K/Akt/mTOR signalling pathways \[[@R23]\]. It has been shown to be one of the most frequently mutated genes in all cancer types, including that of breast, ovary, prostate, glioblastoma and lymphoma. Previous studies have observed that 40% of invasive breast cancers have a loss of *PTEN* heterozygosity, and that the loss of one gene copy is sufficient to disrupt cell signalling and cell growth control. It has also been suggested that carriers of the *PTEN* mutation are at higher risk of developing breast cancers at a younger age \[[@R24]\].

SGCZ (sarcoglycan zeta) {#s2_8}
-----------------------

Our study shows that \~16% of all young patients present a CNA loss mutation encompassing *SGCZ*, with a significantly shorter median survival time for young patients with this mutation of \~6 years in contrast to \~15 years for those without. *SGCZ* (8p22) encodes a protein that is part of the sarcoglycan complex, which plays a role in connecting the inner cytoskeleton to the extracellular matrix, possibly maintaining membrane stability \[[@R25]\]. Although the exact function of *SGCZ* in cancer is not well understood, loss of the chr8p region has been associated with several factors involved in cancer development and progression, such as the tumour having an aggressive histology, increased cell proliferation, and large size as well as the patients having increased early recurrence rate and mortality, and overall poor survival in young women. This region also contains the gene *DLC1* (deleted in liver cancer 1), which has been suggested to act as a tumour suppressor \[[@R26]\]. DLC1 encodes a GAP protein that inhibits the activation of Rho-GTPases, which are often associated with a loss of cell adhesion. *DLC1* expression has been reported to be frequently lost in tumour cells, leading to a constitutive activation of the Rho-GTPases.

CAPN2 (calpain 2) {#s2_9}
-----------------

CAPN2 (cytoband 1q41) was the most frequent CNA gain mutation in our study, with \~37-38% of all young patients harbouring a CAPN2 gain mutation. Calpains are calcium-activated intracellular proteases that have the ability to cleave cytoskeletal proteins, possibly playing a role in regulating cell invasion and migration \[[@R27]\]. A knockdown study of CAPN2 in breast tumour cells resulted in reduced cell migration, proliferation, as well as reduced Akt activation, increased FoxO nuclear localization and p27 expression \[[@R27]\]. It was suggested that CAPN2 promotes cell proliferation through the Akt-FoxO-p27 signalling pathway.

NAALADL2 (N-acetyl-L-aspartyl-L-glutamate peptidase-like 2) {#s2_10}
-----------------------------------------------------------

Our study shows that \~16% of all young patients present a CNA gain mutation encompassing NAALADL2. NAALADL2 is a member of the NAALADase protein family which act as matrix metalloproteases and have the ability to alter the tumour environment. Microarray studies have shown that NAALADL2 is often overexpressed in prostate and colon cancers and stimulates a migratory and metastatic phenotype. A proposed mechanism is that since NAALADL2 has been found to be basal-localized, it may enhance interaction of tumour cells with the extracellular matrix surrounding the tumour and provide a mechanism for the tumour cells to escape \[[@R28]\]. Subsequent survival analysis shows that patients with NAALADL2 overexpression have a 45% chance of surviving up to 5 years as opposed to 93% for patients with low NAALADL2 expression. It remained prognostic for recurrence rate even after correction for clinical variables such as tumour stage and grade. Expression array analyses also associated its overexpression to changes in the epithelial-to-mesenchymal transition (EMT) and cell adhesion pathways.

Pathway enrichment analysis {#s2_11}
---------------------------

A pathway enrichment analysis using the ANNOVAR gene list (174 genes) via the Enrichr REACTOME database reveals a significant overrepresentation of phospholipid signaling (*MTMR14*,*PTEN*,*PIP4K2A*) and adherens junction (*CDH12*, *CDH18*, *CDH7*) pathways (*p* \< 0.05) in the identified young-specific recurrent CNA regions with genes. Both enriched pathways are highly relevant to cancer development and progression.

Phospholipid signaling {#s2_12}
----------------------

Aside from playing an important role in structural components, lipids also have a role in signalling processes \[[@R29], [@R30]\]. These lipid molecules aggregate to form lipid rafts as highly specific platforms for cell signalling, carrying signals from activated growth factor receptors to the intracellular machinery \[[@R31]\]. These receptors recruit signalling effectors that induce cell proliferation and reduce cell death, dysregulation of which contributes to cancer development and progression. The phosphatidylinositol (3,4,5)-trisphosphate molecule, also known as PIP3, is generated by PI3K and leads to activation of downstream signaling components. A well-known consequence is recruitment and activation of protein kinase Akt, which can phosphorylate a variety of substrates, which in turn activate cell growth, apoptosis and cell cycle processes. PIP3 is a substrate for phosphatase and tensin homologue (PTEN), which is required for dephosphorylation of PIP3 into PIP2, essential for inhibition of the AKT pathway. Dysregulation of these pathways is frequent in many cancer types.

Cell adhesion {#s2_13}
-------------

Cellular adhesion plays a major role in maintaining the integrity of normal cell-cell connections, and disruption in this pathway has been strongly associated with metastasis in cancers. Adherens junctions, which are sites of intracellular signalling and anchoring, provide strong bonds between adjacent cell membranes. The molecular processes governing cell-cell adhesion are very finely controlled, since they inhibit epithelial-mesenchymal transition (EMT) that is normally present during embryogenesis and tissue repair. Characteristics of EMT include a loss in intercellular adhesion and enhancement of cell migration, leading to a more motile phenotype \[[@R32]\]. Notably, the adherens junctions are lost during the process of EMT, which increases the risk of cancer progression such as metastasis. In normal tissues, epithelial cells are tightly bound to one another. However, in advanced cancer, many epithelial tumour cells show loss of cell-cell adhesion and increased tissue invasion. Tumours featuring local spreading and invasion are suggested to have a more aggressive phenotype and be associated with a higher mortality rate of the patient. This phenomenon has been widely seen in various cancer types, including breast, colon, prostate, ovarian and other types of cancer \[[@R33]\].

CONCLUSIONS {#s3}
===========

Applying the graph-based algorithm to the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) breast cancer dataset, we have identified and validated 81 recurrent CNA gain regions and 25 validated recurrent CNA loss regions specific to young-Women's breast cancers. As well, we have located the corresponding candidate protein encoding genes that are encompassed in these regions. The graph-based algorithm guarantees that the identified CNA regions are the most frequent and that the minimal regions have been delineated.

Identification of molecular alterations associated with disease outcome may improve risk assessment and treatments for aggressive breast cancer, especially for young women. It can give new insights into the role of CNAs in cancer predisposition, development and progression as well as contribute to a more accurate and complete human cancer genome sequence reference. We hope that the results of this study will in the future, facilitate the development of screening methods for breast cancer biomarker discovery, especially in young women, as more prospective samples become available.

Since CNAs are fairly large in size, in the future it would be interesting to characterize further the non-coding CNA regions we have identified and their role in regulating gene expression levels either in cis or trans.

MATERIALS AND METHODS {#s4}
=====================

Data source {#s4_1}
-----------

All breast cancer data are retrieved from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) \[[@R22]\], which is a novel dataset consisting of comprehensive clinical features such as breast cancer-specific survival data, PAM50 subtypes, ER/PR/HER2 status, tumour grade and tumour sizes. Each case has corresponding whole gene expression profiles (Illumina HT-12 v3 platform), SNPs and somatic DNA copy-number profiling data (Affymetrix Human SNP 6.0 platform). Treatments for the patients are homogeneous among each clinically relevant group: almost all ER-positive/LN-negative patients did not receive chemotherapy, while ER-negative/LN-positive patients did receive chemotherapy. Furthermore, the METABRIC cohort consists of cohorts prior to the usage of Herceptin/trastazumab in standard clinical care. Therefore, the outcome of HER2 positive patients reflects the poor prognosis in such patients before the introduction of this targeted therapy \[[@R22]\].

All samples are derived from \~2,000 clinically annotated primary fresh-frozen breast cancer specimens from tumour banks in the UK and Canada (a discovery set of 997 primary tumours and a validation set of 995 tumours were divided by METABRIC). All genomic and clinically annotated data are available at the European Genome-Phenome Archive (<http://www.ebi.ac.uk/ega/>), under accession number EGAS00000000083 \[[@R22]\]. The individual CNA calls of the \~2,000 individual samples are pre-existing from the METABRIC study and downloaded from EGAS00000000083 \[[@R22]\]. Circular binary segmentation (CBS) method is used for making individual CNA calls. CBS is a segmentation-based method that scans for change points in an ordered sequence of copy number values to delineate segments with different distribution of the values (measured by having different means). In other words, it will recursively divide up the chromosome until segments that have probe distribution different than neighbours have been identified \[[@R41]\].

Representing CNAs as an interval graph {#s4_2}
--------------------------------------

Figure [8A](#F8){ref-type="fig"} shows examples of five individual patient level CNA segments (CNA 1, CNA 2, CNA 3, CNA 4, CNA 5) on the same chromosome. Each of the five CNAs contains chromosomal-specific start (left) and end (right) positions. To identify the common regions of individual patient level CNAs on the same chromosome, the intersection among the individual patient level CNAs can be represented as an interval graph, treating each called individual patient level CNA as a vertex of the graph and connecting two vertices only if the corresponding intervals have an intersecting region. Thus, the constructed interval graph *G*(*V, E*) is comprised of a set of vertices *V*, where each vertex (*v* ϵ *V*) corresponds to a specific interval of the individual patient level CNA and each edge ({*u*, *v*} ϵ *E*) connects two intersecting intervals *u* and *v*. In Figure [8B](#F8){ref-type="fig"}, an example of the interval graph is shown where CNA 1 through CNA 4 are the intervals (nodes of the graph or individual patient level CNAs) and an edge connects two nodes (individual patient level CNAs) if the intervals overlap.

![Representing CNAs as an interval graph\
(**A**) CNA 1, CNA 2, CNA 3, CNA 4, CNA 5 are individual patient level CNAs on a specific chromosome. Each of the CNAs has chromosome start and end positions. (**B**) This is an interval graph where CNA 1, CNA 2, CNA 3, CNA 4, CNA 5 are the individual patient level CNAs in (A). The edge between each of two vertices in the graph represents the two individual patient level CNAs sharing a piece of common regions on the chromosome.](oncotarget-09-11541-g008){#F8}

To find maximal cliques in an interval graph constructed from individual patient level CNAs, we applied Gentlemen and Vandal's algorithm \[[@R34]\]. The main idea of the algorithm is to sort the vertices based on their chromosomal end positions. The ordering is important because it allows the algorithm to discard vertices in each iteration without losing the triangulation property. The input of the algorithm is the individual patient level CNAs on a specific chromosome, which includes two parameters for each CNA segment: start and end positions (base pair).

Each of the identified maximal cliques is a recurrent CNA, which is common in multiple patients. The shared region of the recurrent CNA across multiple patients is the minimal common region (MCR) of the CNA, which has the potential to harbour cancer causing/associated genes. In practice, the size of the maximal cliques should be at least 2 and the size of the MCRs should be at least 1kb. It should be noted that we need to analyse CNA gains and losses separately. More details of the algorithm and its applications can be found in \[[@R35]\].

Survival analysis {#s4_3}
-----------------

Disease (breast cancer) specific survival analysis was performed for both the mutation status (CNA gain, CNA loss) by the product-limit method or The Kaplan-Meier method and the expression level of the corresponding genes that are encompassed in the validated recurrent CNA regions using the Cox proportional hazard model \[[@R36]\]. All analyses were performed using Survival R package (<https://cran.r-project.org/web/packages/survival/index.html>).

eQTL analysis {#s4_4}
-------------

An expression quantitative trait locus (eQTL) is a locus that explains a portion of the genetic variance of a gene expression phenotype. An eQTL analysis tests for direct associations between markers of genetic variation with gene expression levels; that is, to evaluate the association between gene expression and CNA mutation status. Logistic regression is used to estimate the probability p associated with a dichotomous response for various values of an explanatory variable. In this case, the response (dependent) variable is gene expression (binarized-by-mean) and the predictor (independent) variable is CNA status.

Functional analysis {#s4_5}
-------------------

Functional analysis such as enrichment and annotations have been carried out using software (Enrichr and ANNOVAR) to determine whether the identified CNA regions with protein coding genes are enriched in any interesting pathways or functions. Enrichr software \[[@R37]\] contains a diverse and up-to-date collection of over 100 gene-set libraries available for analysis and download. It is used to perform pathway enrichment analysis on the identified young-specific genes to identify which pathways are over-represented in the gene-set. ANNOVAR \[[@R38]\] is a perl command line program for genome annotation. This region-based annotation is used to identify affected genomic regions that lie outside of the protein-coding regions.

Biological visualization {#s4_6}
------------------------

In order to aid in clearer visualization of and assist interpretation of the results, software programs Oncoprint \[[@R39]\] and CIMminer \[[@R40]\] were used to generate heatmap visualizations for the identified candidate regions. Oncoprint is included in the R package ComplexHeatMap, and it is a way to visualize multiple genomic alteration events in the format of a heatmap. This is used to visualize the frequencies of CNA mutation for each of the young-specific regions with genes in Discovery and Validation datasets. CIMminer generates color-coded Clustered Image Maps (CIMs) to portray "high-dimensional" data sets such as gene expression profiles. It is used to visualize the relative expression levels in terms of colour intensity for each of the identified young-specific genes.

SUPPLEMENTARY MATERIALS AND TABLES {#s5}
==================================
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